echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Heavy! 2022 NICE Gout Guidelines Released (FlowChart Included)

    Heavy! 2022 NICE Gout Guidelines Released (FlowChart Included)

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    *For medical professionals only

    Exclusive flowchart, hurry up and collect!


    Gout is a long-term disease, in which an increase in serum uric acid levels leads to the formation of uric acid monosodium crystals, which leads to severe joint pain and inflammation, recurrent attacks and progressions


    • Uric acid-lowering therapy (ULT) should be managed using standard treatments, with the goal of controlling blood uric acid levels at < 360 μmol/L (6 mg/dl).



    • Chronic kidney disease of stage 3-5;

    • In the use of diuretics;

    • There are tophis;

    • Chronic gouty arthritis



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.